Investigating KLF2 as a protective target for diabetic kidney disease
KLF2 is a novel endoprotective target for DKD
This study is looking at how a special protein called KLF2 can help protect both the kidneys and the heart in people with diabetic kidney disease, with the goal of finding new treatments to improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11194403 on NIH RePORTER |
What this research studies
This research focuses on diabetic kidney disease (DKD) and its link to cardiovascular disease (CVD), aiming to develop new treatments that provide protection for both the kidneys and the heart. The study examines the role of a specific protein, KLF2, which is involved in protecting endothelial cells from injury caused by diabetes. By understanding how KLF2 functions and its regulatory mechanisms, the research seeks to identify potential therapeutic strategies that could improve patient outcomes in those suffering from DKD and related cardiovascular issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with diabetic kidney disease who may also be at risk for cardiovascular disease.
Not a fit: Patients without diabetic kidney disease or those with other unrelated kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly reduce the risk of cardiovascular complications in patients with diabetic kidney disease.
How similar studies have performed: Previous research has shown promising results in targeting KLF2 for protective effects in cardiovascular conditions, suggesting a potential for success in this novel application.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: He, John Cijiang — Icahn School of Medicine at Mount Sinai
- Study coordinator: He, John Cijiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.